Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Core Viewpoint - Sutro Biopharma, Inc. has announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at $13.98 per share, aiming to raise approximately $110.0 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering consists of shares being offered solely by Sutro, with the expected closing date around February 11, 2026, pending customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as BVF Partners L.P., Samsara BioCapital, and others [2]. Group 2: Use of Proceeds - Sutro intends to utilize the net proceeds from the offering for general corporate purposes, which may encompass funding research, clinical development, manufacturing of product candidates, increasing working capital, and potential acquisitions or investments [3]. Group 3: Company Overview - Sutro Biopharma is focused on advancing a next-generation antibody-drug conjugate (ADC) platform aimed at delivering innovative cancer therapies, with a pipeline targeting significant oncology markets that currently have limited treatment options [6].